Injection drug use and associated hospital admissions are increasingly common in Canada
The number of people who inject drugs in Canada increased from 130 000 in 2011 to 171 900 in 2016.1 Reported hospital admissions for patients with injection-associated infective endocarditis in Ontario increased 5-fold from 34 in 1997 to 176 in 2014.2
People who inject drugs may not be comfortable disclosing substance use
Clinicians should use a nonjudgmental approach to ask their patients about type, quantity and frequency of substance use. Illicit substance use is stigmatized and criminalized, which affects hospital care.3,4 People who inject drugs ask for care that prioritizes trust and relationships, recognizes power imbalances and gives patients space.3
Starting treatment for substance use disorders in hospital improves outcomes
A randomized controlled trial5 and several cohort studies4,6 found inhospital initiation of opioid agonist treatment (e.g., buprenorphine or methadone) for opioid use disorder was associated with increased engagement with treatment and decreased readmissions or death, compared with outpatient referrals. All physicians can prescribe buprenorphine or methadone in hospital, although some provincial medical regulators require certification to initiate opioid agonist treatment. Addiction medicine consultation services can assist with complex diagnosis and management issues, including stimulant and polysubstance use disorders.4
Effectively treating opioid withdrawal reduces premature patient-initiated discharges against medical advice
People who inject drugs describe leaving hospital prematurely because of undertreated withdrawal and pain.3 Most people who inject drugs use opioids,1 and opioid medications are far more effective than nonopioids (e.g., clonidine) at relieving opioid withdrawal symptoms and facilitating hospital care.3,4 If patients decline opioid agonist treatment, physicians should consider frequent dosing of short-acting opioids (e.g., hydromorphone every 3 h), titrated to symptom relief.4 Treating withdrawal or pain with opioids does not “worsen” addiction. Shared decision-making is essential.4
Hospitals should offer harm reduction services
Hospitals need to change traditional abstinence-only policies.4 Harm reduction services, such as peer support, sterile injection equipment and disposal containers, take-home naloxone kits and supervised consumption facilities, should be offered by hospitals. When provided, these evidence-based services help reduce risks of infection and overdose among inpatients.4
Footnotes
Competing interests: Thomas Brothers is supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, Killam Postgraduate Scholarship, Ross Stewart Smith Memorial Fellowship in Medical Research and Clinician Investigator Program Graduate Stipend (all from Dalhousie University Faculty of Medicine), a Canadian Institutes of Health Research Fellowship (CIHR-FRN no. 171259), and the Research in Addiction Medicine Scholars (RAMS) Program (National Institute on Drug Abuse; no. R25DA033211). No other competing interests were declared.
This article has been peer reviewed.
References
- 1.Jacka B, Larney S, Degenhardt L, et al. Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada. Am J Public Health 2020; 110:45–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Coverdale N, Brogly S, Payne D, et al. Rates of infective endocarditis in substance use disorder and associated costs in Ontario. Can J Addict 2019;10:36–43. [Google Scholar]
- 3.McCall J, Pauly B. Sowing a seed of safety: providing culturally safe care in acute care settings for people who use drugs. J Mental Health Addic Nurs 2019;3:e1–7. [Google Scholar]
- 4.Allen D, Brouwer J, Dong K, et al. Management of substance use in acute care settings in Alberta: guidance document. Edmonton: Canadian Research Initiative on Substance Misuse (CRISM); 2020. Available: https://crismprairies.ca/management-of-substance-use-in-acute-care-settings-in-alberta-guidance-document/ (accessed 2020 Dec. 4). [Google Scholar]
- 5.Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014;174: 1369–76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Marks LR, Munigala S, Warren DK, et al. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis 2019;68:1935–7. [DOI] [PMC free article] [PubMed] [Google Scholar]